Table 1. Baseline Characteristics of Participants With TIA and Control Participants Without TIA.
Entire follow-up period (1948-2017) | Current epoch (2000-2017) | |||||||
---|---|---|---|---|---|---|---|---|
With TIA (n = 435)a | Without TIA (n = 2175) | Absolute difference (95% CI) | P value | With TIA (n = 118) | Without TIA (n = 590) | Absolute difference (95% CI) | P value | |
Age, mean (SD), y | 71.9 (11.2) | 71.3 (11.3) | 0.55 (−0.61 to 1.71) | .35 | 73.2 (13.4) | 72.8 (13.3) | 0.39 (−2.25 to 3.03) | .77 |
Sex, No. (%) | ||||||||
Women | 229 (53) | 1145 (53) | 0.00 (−0.05 to 0.05) | >.99 | 65 (55) | 325 (55) | 0.00 (0.10 to 0.10) | >.99 |
Men | 206 (47) | 1030 (47) | 0.00 (−0.05 to 0.05) | 53 (45) | 265 (45) | 0.00 (0.10 to 0.10) | ||
Blood pressure, mean (SD), mm Hg | ||||||||
Systolic | 144 (23) | 136 (21) | 7.17 (4.80 to 9.53)a | <.001 | 135 (21) | 130 (20) | 4.20 (0.22 to 8.19)a | .04 |
Diastolic | 78 (13) | 77 (11) | 1.00 (0.29 to 2.29)a | .13 | 73 (11) | 73 (11) | 0.25 (−1.88 to 2.37)a | .82 |
Hypertension treatment, No./total (%) | 198/422 (47) | 700/2075 (34) | 13.2 (8.0 to 18.4) | <.001 | 67/115 (58) | 248/584 (42) | 15.8 (5.9 to 25.6) | .002 |
Stage I hypertension, No./total (%) | 315/430 (73) | 1223/2156 (57) | 16.5 (2.1 to 11.9) | <.001 | 76/117 (65) | 318/587 (54) | 10.8 (1.2 to 20.3) | .03 |
Diabetes mellitus, No./total (%) | 59/346 (17) | 198/1729 (11) | 5.6 (1.4 to 9.8) | .004 | 27/101 (27) | 71/512 (14) | 12.8 (3.7 to 22.0) | .001 |
Atrial fibrillation, No. (%) | 42 (10) | 115 (5) | 4.4 (1.4.32 to 7.3) | .001 | 19 (16) | 41 (7) | 9.1 (2.2 to 16.1) | .001 |
Current smoking, No./total (%) | 100/409 (24) | 397/1994 (20) | 4.5 (0.2 to 9.0) | .04 | 16 (14) | 75/586 (13) | 0.8 (−7.5 to 6.0) | .82 |
Coronary heart disease, No. (%) | 103 (24) | 330 (15) | 8.5 (4.2 to 12.8) | <.001 | 23 (19) | 71 (12) | 7.5 (−0.2 to 15.1) | .03 |
Abbreviation: TIA, transient ischemic attack.
For the continuous variables systolic and diastolic blood pressure, data are reported as absolute mean difference and corresponding 95% CI.